人のウォール街のアナリストによると、Alps Group Incの収益見積もりは$から$の範囲です。
Alps Group Incの収益品質スコアはどれくらいですか?
Alps Group Incの収益品質スコアは/です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
Alps Group Incはいつ収益を報告しますか?
Alps Group Incの次の収益報告は2026-06-15に予定されています
Alps Group Incの予想収益はいくらですか?
ウォール街のアナリストによると、Alps Group Incの予想収益は$です。
Alps Group Incは収益予想を上回りましたか?
Alps Group Incの最近の収益は$で、予想を。
主要データ
前終値
$0.23
始値
$0.221
当日レンジ
$0.22 - $0.28
52週レンジ
$0.26 - $15
取引高
120.4K
平均取引高
297.3K
配当利回り
--
1株当たり利益(TTM)
-0.51
時価総額
$44.8M
GLLIRとは何ですか?
Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.